Literature DB >> 16376158

Carbonic anhydrase inhibitors and hypoxic pulmonary vasoconstriction.

Erik R Swenson1.   

Abstract

Acetazolamide and other related carbonic anhydrase (CA) inhibitors have had a long history of effectiveness in prevention and treatment of acute mountain sickness (AMS) and remain the standard of care for this indication. Despite many decades of CA inhibitor use for AMS, the possibility has never been seriously entertained that these drugs might also afford protection against high altitude pulmonary edema (HAPE). In this paper, I will present our evidence and supporting data of others, that acetazolamide has inhibitory effects on the hypoxic response of the pulmonary circulation that may be useful in HAPE. Data from pulmonary artery smooth muscle cells, isolated perfused lungs, and live unanethetized animals all point to a potent reduction in hypoxic pulmonary vasoconstriction (HPV) by acetazolamide that may have clinical utility in HAPE and possibly other pulmonary hypertensive disorders. Astonishingly, the efficacy of acetazolamide as a HPV inhibitor does not appear to be related to carbonic anhydrase inhibition, since other potent CA inhibitors have no effect on HPV either in the conscious dog or on hypoxic calcium (Ca(2+)) signalling in rat pulmonary artery smooth muscle cells, despite enzyme presence in these cells. Although we have not yet determined the mechanism of action for acetazolamide in HPV, we have ruled out actions on membrane L-type Ca(2+) channels, normoxic and hypoxic membrane potential and rho-kinase activation. Based upon these negative findings in isolated pulmonary artery smooth muscle cells and preliminary data in Ca(2+) free media we propose that acetazolamide may act at the level of Ca(2+) release from the sarcoplasmic reticulum, a process which initiates and amplifies cell membrane Ca(2+) channel opening. In further work, we have developed and will use a methylated analog of acetazolamide to yield a molecule lacking CA inhibiting activity, but which in most other respects (size, pK(a), heterocyclic ring structure, electrostatic charge distribution) is equivalent to acetazolamide.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16376158     DOI: 10.1016/j.resp.2005.10.011

Source DB:  PubMed          Journal:  Respir Physiol Neurobiol        ISSN: 1569-9048            Impact factor:   1.931


  8 in total

1.  Effect of acetazolamide on pulmonary and muscle gas exchange during normoxic and hypoxic exercise.

Authors:  Amy M Jonk; Irene P van den Berg; I Mark Olfert; D Walter Wray; Tatsuya Arai; Susan R Hopkins; Peter D Wagner
Journal:  J Physiol       Date:  2007-01-11       Impact factor: 5.182

2.  Pulmonary vasodilation by acetazolamide during hypoxia: impact of methyl-group substitutions and administration route in conscious, spontaneously breathing dogs.

Authors:  Philipp A Pickerodt; Roland C Francis; Claudia Höhne; Friederike Neubert; Stella Telalbasic; Willehad Boemke; Erik R Swenson
Journal:  J Appl Physiol (1985)       Date:  2014-01-30

Review 3.  Interventions for preventing high altitude illness: Part 1. Commonly-used classes of drugs.

Authors:  Víctor H Nieto Estrada; Daniel Molano Franco; Roger David Medina; Alejandro G Gonzalez Garay; Arturo J Martí-Carvajal; Ingrid Arevalo-Rodriguez
Journal:  Cochrane Database Syst Rev       Date:  2017-06-27

4.  Hypoxia, not pulmonary vascular pressure, induces blood flow through intrapulmonary arteriovenous anastomoses.

Authors:  Joshua C Tremblay; Andrew T Lovering; Philip N Ainslie; Mike Stembridge; Keith R Burgess; Akke Bakker; Joseph Donnelly; Samuel J E Lucas; Nia C S Lewis; Paolo B Dominelli; William R Henderson; Giulio S Dominelli; A William Sheel; Glen E Foster
Journal:  J Physiol       Date:  2014-12-23       Impact factor: 5.182

Review 5.  Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19).

Authors:  Isaac Solaimanzadeh
Journal:  Cureus       Date:  2020-03-20

Review 6.  Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders.

Authors:  Akylbek Sydykov; Argen Mamazhakypov; Abdirashit Maripov; Djuro Kosanovic; Norbert Weissmann; Hossein Ardeschir Ghofrani; Akpay Sh Sarybaev; Ralph Theo Schermuly
Journal:  Int J Environ Res Public Health       Date:  2021-02-10       Impact factor: 3.390

Review 7.  High-altitude illnesses: Old stories and new insights into the pathophysiology, treatment and prevention.

Authors:  Martin Burtscher; Urs Hefti; Jacqueline Pichler Hefti
Journal:  Sports Med Health Sci       Date:  2021-04-16

8.  Carbonic Anhydrase III Promotes Cell Migration and Epithelial-Mesenchymal Transition in Oral Squamous Cell Carcinoma.

Authors:  Yin-Hung Chu; Chun-Wen Su; Yih-Shou Hsieh; Pei-Ni Chen; Chiao-Wen Lin; Shun-Fa Yang
Journal:  Cells       Date:  2020-03-13       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.